Common Contracts
95 similar Open Market Sale contracts by Praxis Precision Medicines, Inc., Gamida Cell Ltd., VBI Vaccines Inc/Bc, others
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • March 5th, 2024 • Praxis Precision Medicines, Inc. • Pharmaceutical preparations • New York
Praxis Precision Medicines, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $150 million on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENT1Open Market Sale • February 29th, 2024 • Chimerix Inc • Pharmaceutical preparations • New York
Chimerix, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), having an aggregate offering price of up to $75,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • December 7th, 2023 • Praxis Precision Medicines, Inc. • Pharmaceutical preparations • New York
Praxis Precision Medicines, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $75 million on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • November 14th, 2023 • Rezolute, Inc. • Pharmaceutical preparations • New York
Rezolute, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • November 9th, 2023 • P3 Health Partners Inc. • Services-health services • New York
P3 Health Partners Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s Class A common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $75 million on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • November 2nd, 2023 • BioXcel Therapeutics, Inc. • Pharmaceutical preparations • New York
BioXcel Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), having an aggregate offering price of up to the Maximum Program Amount (as defined herein) on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • August 16th, 2023 • ImmunoPrecise Antibodies Ltd. • Pharmaceutical preparations • New York
ImmunoPrecise Antibodies Ltd., a corporation continued under the Business Corporations Act (British Columbia) (the "Company"), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the "Agent"), common shares of the Company, without par value (the "Common Shares"), on the terms set forth in this agreement (this "Agreement").
AMENDED & RESTATED OPEN MARKET SALE AGREEMENTSMOpen Market Sale • August 14th, 2023 • Gamida Cell Ltd. • Biological products, (no disgnostic substances) • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • August 3rd, 2023 • Omega Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • April 25th, 2023 • Arbe Robotics Ltd. • Services-computer integrated systems design • New York
Arbe Robotics Ltd., a company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), ordinary shares of the Company, par value NIS 0.000216 per share (the “Ordinary Shares”), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • April 3rd, 2023 • Alpha Tau Medical Ltd. • Surgical & medical instruments & apparatus • New York
Alpha Tau Medical Ltd., a company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), ordinary shares of the Company, no par value per share (the “Ordinary Shares”), having an aggregate offering price of up to $75,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • February 7th, 2023 • Praxis Precision Medicines, Inc. • Pharmaceutical preparations • New York
Praxis Precision Medicines, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $125 million on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENT1Open Market Sale • December 8th, 2022 • Arrowhead Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), having an aggregate offering price of up to $250,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • November 18th, 2022 • Iovance Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Iovance Biotherapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.000041666 per share (the “Common Shares”), having an aggregate offering price of up to $500,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • November 1st, 2022 • Jefferies Financial Group Inc. • Security brokers, dealers & flotation companies • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • August 26th, 2022 • VBI Vaccines Inc/Bc • Pharmaceutical preparations • New York
VBI Vaccines Inc., a company incorporated under the Business Corporations Act (British Columbia) (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), common shares of the Company, no par value per share (the “Common Shares”), having an aggregate offering price of up to $125,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • August 5th, 2022 • Protagonist Therapeutics, Inc • Pharmaceutical preparations • New York
Protagonist Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.00001 per share (the “Common Shares”), having an aggregate offering price of up to $100,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • August 1st, 2022 • Compass Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • July 12th, 2022 • Greenwich LifeSciences, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • June 10th, 2022 • TFF Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
TFF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • May 24th, 2022 • Augmedix, Inc. • Services-business services, nec • New York
Augmedix. Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • April 22nd, 2022 • aTYR PHARMA INC • Biological products, (no disgnostic substances) • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • April 19th, 2022 • Sol-Gel Technologies Ltd. • Pharmaceutical preparations • New York
Sol-Gel Technologies Ltd., a company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), ordinary shares of the Company, par value NIS 0.1 per share (the “Ordinary Shares”), on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • April 5th, 2022 • Mesa Laboratories Inc /Co/ • Industrial instruments for measurement, display, and control • New York
Mesa Laboratories, Inc., a Colorado corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, no par value per share (the “Common Shares”), having an aggregate offering price of up to $150,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • March 4th, 2022 • Intellia Therapeutics, Inc. • In vitro & in vivo diagnostic substances • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • March 1st, 2022 • Cara Therapeutics, Inc. • Pharmaceutical preparations • New York
Cara Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”) on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • November 9th, 2021 • Cue Biopharma, Inc. • Pharmaceutical preparations • New York
Cue Biopharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.001 per share (the “Common Shares”), having an aggregate offering price of up to $80,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • November 4th, 2021 • Puma Biotechnology, Inc. • Pharmaceutical preparations • New York
Puma Biotechnology, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • November 3rd, 2021 • Praxis Precision Medicines, Inc. • Pharmaceutical preparations • New York
Praxis Precision Medicines, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $125 million on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • November 2nd, 2021 • Corvus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Corvus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $40,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • September 13th, 2021 • Gamida Cell Ltd. • Biological products, (no disgnostic substances) • New York
Gamida Cell Ltd., a limited liability company organized under the laws of the State of Israel (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s ordinary shares with a nominal value of New Israeli Shekel 0.01 per share (the “Ordinary Shares”), on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • September 3rd, 2021 • VBI Vaccines Inc/Bc • Pharmaceutical preparations • New York
VBI Vaccines Inc., a company incorporated under the Business Corporations Act (British Columbia) (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), common shares of the Company, no par value per share (the “Common Shares”), having an aggregate offering price of up to $125,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • August 27th, 2021 • NeuBase Therapeutics, Inc. • Pharmaceutical preparations • New York
NeuBase Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common stock, par value $0.0001 per share (the “Common Shares”), having an aggregate offering price of up to $50,000,000 on the terms set forth in this agreement (this “Agreement”).
OPEN MARKET SALE AGREEMENT1Open Market Sale • August 17th, 2021 • Ardelyx, Inc. • Pharmaceutical preparations • New York
OPEN MARKET SALE AGREEMENTSMOpen Market Sale • June 30th, 2021 • Catabasis Pharmaceuticals Inc • Pharmaceutical preparations • New York
